AU2018358582B2 - Pharmaceutical composition for prevention or treatment of acute myeloid leukemia or metastatic breast cancer - Google Patents

Pharmaceutical composition for prevention or treatment of acute myeloid leukemia or metastatic breast cancer Download PDF

Info

Publication number
AU2018358582B2
AU2018358582B2 AU2018358582A AU2018358582A AU2018358582B2 AU 2018358582 B2 AU2018358582 B2 AU 2018358582B2 AU 2018358582 A AU2018358582 A AU 2018358582A AU 2018358582 A AU2018358582 A AU 2018358582A AU 2018358582 B2 AU2018358582 B2 AU 2018358582B2
Authority
AU
Australia
Prior art keywords
compound
biindolinylidene
imino
ethoxy
flt3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018358582A
Other languages
English (en)
Other versions
AU2018358582A1 (en
Inventor
Pyeong Hwa Jeong
Yong Chul Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pelemed Co Ltd
Original Assignee
Pelemed Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pelemed Co Ltd filed Critical Pelemed Co Ltd
Publication of AU2018358582A1 publication Critical patent/AU2018358582A1/en
Application granted granted Critical
Publication of AU2018358582B2 publication Critical patent/AU2018358582B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2018358582A 2017-10-31 2018-10-30 Pharmaceutical composition for prevention or treatment of acute myeloid leukemia or metastatic breast cancer Active AU2018358582B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20170144142 2017-10-31
KR10-2017-0144142 2017-10-31
PCT/KR2018/013051 WO2019088677A1 (ko) 2017-10-31 2018-10-30 급성 골수성 백혈병 또는 전이성 유방암의 예방 또는 치료용 약제학적 조성물

Publications (2)

Publication Number Publication Date
AU2018358582A1 AU2018358582A1 (en) 2020-05-07
AU2018358582B2 true AU2018358582B2 (en) 2021-06-10

Family

ID=66333236

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018358582A Active AU2018358582B2 (en) 2017-10-31 2018-10-30 Pharmaceutical composition for prevention or treatment of acute myeloid leukemia or metastatic breast cancer

Country Status (12)

Country Link
US (1) US11370779B2 (enExample)
EP (1) EP3705474A4 (enExample)
JP (1) JP7005779B2 (enExample)
KR (1) KR102247795B1 (enExample)
CN (1) CN111542513A (enExample)
AU (1) AU2018358582B2 (enExample)
BR (1) BR112020008499A2 (enExample)
CA (1) CA3080900C (enExample)
MX (1) MX2020004374A (enExample)
PH (1) PH12020550491A1 (enExample)
RU (1) RU2763346C2 (enExample)
WO (1) WO2019088677A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3958830A1 (en) 2019-04-26 2022-03-02 Unilever Global Ip Limited Hair conditioning composition
CN110305056A (zh) * 2019-05-22 2019-10-08 西北大学 靛玉红新衍生物及其药用用途
WO2021090172A1 (en) 2019-11-04 2021-05-14 Ck Biotechnology Co. Compositions and methods for suppressing and/or treating neurodegenerative diseases and/or a clinical condition thereof
KR102296440B1 (ko) * 2019-12-06 2021-09-02 주식회사 펠레메드 신규한 인디루빈 유도체 및 이의 용도
KR102443617B1 (ko) * 2019-12-06 2022-09-16 광주과학기술원 근감소증 또는 근위축증의 예방 또는 치료용 약제학적 조성물
KR20210106155A (ko) 2020-02-20 2021-08-30 한국과학기술원 Ash1l 히스톤 메틸화 효소 활성을 억제하는 페닐카르보노히드라조노일 디시아나이드 유도체 화합물을 포함하는 백혈병의 예방 또는 치료용 조성물
KR102325607B1 (ko) 2020-02-20 2021-11-12 한국과학기술원 Ash1l 히스톤 메틸화 효소 활성을 억제하는 벤조퓨란-피라졸 유도체 화합물을 포함하는 백혈병의 예방 또는 치료용 조성물
KR102278176B1 (ko) 2020-02-20 2021-07-16 한국과학기술원 Ash1l 히스톤 메틸화 효소 활성을 억제하는 벤조디옥솔 유도체 화합물을 포함하는 백혈병의 예방 또는 치료용 조성물
US20220079934A1 (en) * 2020-09-17 2022-03-17 Arog Pharmaceuticals, Inc. Crenolanib for treating pain
KR102744517B1 (ko) * 2022-02-14 2024-12-19 주식회사 펠레메드 신규한 헤테로비시클릭 잔기를 갖는 인디루빈 유도체 및 이의 용도
WO2024181799A1 (ko) * 2023-02-28 2024-09-06 주식회사 씨케이리제온 신규한 인돌린 유도체 및 이의 용도

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000061555A1 (en) * 1999-04-12 2000-10-19 Gerhard Eisenbrand Indigoid bisindole derivatives
WO2011096676A2 (en) * 2010-02-05 2011-08-11 Anygen Co., Ltd. Indirubin-3'-oxime derivatives as potent cyclin dependent kinase inhibitors
EP2518139A1 (en) * 2011-04-27 2012-10-31 Universitätsklinikum Jena Use of indirubin derivatives for producing pluripotent stem cells
WO2013142817A2 (en) * 2012-03-23 2013-09-26 Dennis Brown Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
WO2014153023A1 (en) * 2013-03-14 2014-09-25 City Of Hope 5-bromo-indirubins
US20150259288A1 (en) * 2014-03-14 2015-09-17 City Of Hope 5-bromo-indirubins

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2850652B1 (fr) * 2003-01-31 2008-05-30 Aventis Pharma Sa Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
KR100588803B1 (ko) * 2004-01-27 2006-06-12 학교법인조선대학교 암세포주에 항암활성을 지닌 인디루빈 유도체
CA2633069A1 (en) 2005-12-23 2007-09-07 Centre National De La Recherche Scientifique (Cnrs) New 3'-, 7-substituted indirubins and their applications
ATE529402T1 (de) 2008-08-01 2011-11-15 Centre Nat Rech Scient 3',6-substituierte indirubine und ihre biologischen anwendungen
US10435367B2 (en) * 2013-03-14 2019-10-08 City Of Hope Indirubin derivatives, and uses thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000061555A1 (en) * 1999-04-12 2000-10-19 Gerhard Eisenbrand Indigoid bisindole derivatives
WO2011096676A2 (en) * 2010-02-05 2011-08-11 Anygen Co., Ltd. Indirubin-3'-oxime derivatives as potent cyclin dependent kinase inhibitors
EP2518139A1 (en) * 2011-04-27 2012-10-31 Universitätsklinikum Jena Use of indirubin derivatives for producing pluripotent stem cells
WO2013142817A2 (en) * 2012-03-23 2013-09-26 Dennis Brown Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
WO2014153023A1 (en) * 2013-03-14 2014-09-25 City Of Hope 5-bromo-indirubins
US20150259288A1 (en) * 2014-03-14 2015-09-17 City Of Hope 5-bromo-indirubins

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
Bioorganic & Medicinal Chemistry Letters, 2010, Vol. 20, No. 6, pages 2033-2037 *
Bioorganic & Medicinal Chemistry, 2017, Vol. 25, No. 17, pages 4665-4676 *
CAS Registry Number: 1591767-01-9; STN Entry date 28 April 2014 *
Chemistry & Biodiversity, 2012, Vol. 9, No. 10, pages 2175-2185. *
Journal of Medicinal Chemistry, 2017, Vol. 60, No. 12, pages 4949-4962. *
Leukemia Research, 2013, Vol. 37, No. 4, pages 427-433. *
Molecular Oncology, 2012, Vol. 6, No. 3, pages 276-283. *

Also Published As

Publication number Publication date
KR102247795B9 (ko) 2023-04-12
BR112020008499A2 (pt) 2020-10-20
EP3705474A1 (en) 2020-09-09
CA3080900A1 (en) 2019-05-09
KR20190049584A (ko) 2019-05-09
MX2020004374A (es) 2020-11-11
US11370779B2 (en) 2022-06-28
CA3080900C (en) 2022-10-25
AU2018358582A1 (en) 2020-05-07
PH12020550491A1 (en) 2021-01-11
RU2763346C2 (ru) 2021-12-28
WO2019088677A1 (ko) 2019-05-09
US20200270229A1 (en) 2020-08-27
JP2021501208A (ja) 2021-01-14
JP7005779B2 (ja) 2022-02-10
RU2020115581A3 (enExample) 2021-12-02
RU2020115581A (ru) 2021-12-02
CN111542513A (zh) 2020-08-14
KR102247795B1 (ko) 2021-05-04
EP3705474A4 (en) 2021-06-09

Similar Documents

Publication Publication Date Title
AU2018358582B2 (en) Pharmaceutical composition for prevention or treatment of acute myeloid leukemia or metastatic breast cancer
US6403588B1 (en) Imidazopyridine derivatives
TW200307535A (en) Therapeutic agent for cancer
WO2014165090A1 (en) Compounds for the treatment of tuberculosis
HUE027534T2 (en) Notch pathway inhibitory compound
AU2019218187B2 (en) Dioxinoquinoline compounds, preparation method and uses thereof
CN108530310A (zh) 2-(取代苯杂基)芳香甲酸类fto抑制剂，其制备方法及其应用
EP4329746A1 (en) Phthalimido cereblon complex binders and transcription factor degraders and methods of use
JP2019512459A (ja) ７員環化合物、その調製方法、その医薬組成物、およびその使用
KR20240145475A (ko) 고형 종양의 치료를 위한 유비퀴틴-특이적-프로세싱 프로테아제 1 (usp1) 억제제
WO2013170758A1 (zh) 含稠环结构的苯甲酰胺类化合物及其作为抗肿瘤药物应用
WO2019029629A1 (en) SUBSTITUTED PYRAZOLOPYRIMIDINES FOR USE AS KINASE INHIBITORS
EA037876B1 (ru) Соединение в виде аминозамещенного шестичленного гетероциклического кольца с гетероатомом азота, его получение и использование
KR20210047850A (ko) 급성 골수성 백혈병 또는 전이성 유방암의 예방 또는 치료용 약제학적 조성물
US10173995B2 (en) Pyridine compounds used as PI3 kinase inhibitors
AU757611B2 (en) Optically active pyrrolopyridazine compounds
KR20220114569A (ko) 항암 화합물로서 cullin 3 어댑터 kbtbd4의 모듈레이터
CN109111439B (zh) 一种酰胺类化合物及包含该化合物的组合物及其用途
WO2018204286A1 (en) An anti-cancer stemness drug
CN109134433B (zh) 一种抑制rock的化合物及其应用
JPS625968A (ja) 新規ｎ置換３，４―ジヒドロピリミジン誘導体および血管拡張剤
KR20190063746A (ko) p34 단백질 및 NEDD4-1 단백질의 결합 억제제로서의 신규 화합물 및 이의 용도
KR101995533B1 (ko) [1,2,4]트리아졸로[4,3-a]퀴노잘린 아미노 페닐 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 포함하는 BET 단백질 관련 질환의 예방 또는 치료용 약학적 조성물
WO2025162428A1 (en) Cyclic peptide compounds and compositions as ras inhibitors
CA3241699A1 (en) Compounds for treatment of cancer

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)